USFDA approves Takeda Fruzaqla for previously treated Metastatic Colorectal Cancer Ruchika Sharma10 Nov 2023 1:51 PM ISTOsaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA (fruquintinib), an oral targeted therapy for...
FIRST: Takeda gets USFDA nod for Adzybm for rare inherited Blood Clotting Disorder Ruchika Sharma10 Nov 2023 11:39 AM ISTOsaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the...
Failed Drugs, Loss of Patent: Japanese drugmaker Takeda slashes full-year profit forecast by 36 percent Ruchika Sharma26 Oct 2023 3:21 PM ISTTokyo: Japan's biggest drugmaker Takeda Pharmaceutical has slashed its full-year profit forecast by 36% as it contends with disappointments in...
Takeda to voluntary withdraw lung cancer therapy Exkivity Ruchika Sharma4 Oct 2023 4:30 PM ISTOsaka: Takeda has announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will be working with the FDA...
Takeda gets USFDA nod for subcutaneous administration of Entyvio for ulcerative colitis Ruchika Sharma29 Sept 2023 12:30 PM ISTOsaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) administration of ENTYVIO...
USFDA accepts BLA for subcutaneous administration of Takeda Entyvio for maintenance therapy in Crohn's Disease Ruchika Sharma14 Sept 2023 3:58 PM ISTOsaka: Takeda today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA)...
ImmunoGen, Takeda ink pact to develop, commercialize Elahere in Japan Ruchika Sharma30 Aug 2023 1:00 PM ISTPer the agreement, ImmunoGen has retained exclusive production rights and will supply product for development and commercial use in Japan.
Takeda voluntary withdraws US Biologics License Application for Dengue vaccine Ruchika Sharma12 July 2023 3:30 PM ISTTakeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic "backbone"...
Takeda gets USFDA nod to expand use of HYQVIA to treat primary immunodeficiency in children Ruchika Sharma14 April 2023 10:00 AM ISTPrimary Immunodeficiency is an umbrella term to describe a group of more than 400 disorders that affect the body's immune system, increasing...
Takeda declares positive results in Phase 2b Study of TAK-279 in people with moderate-to-severe Plaque Psoriasis Ruchika Sharma20 March 2023 3:44 PM ISTPsoriasis is a chronic autoimmune disease in which the body's immune system causes skin cells to multiply too quickly.
Takeda concludes acquisition of Nimbus Therapeutics' TYK2 Program Subsidiary Ruchika Sharma9 Feb 2023 11:22 AM ISTOsaka: Takeda has announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. ("Lakshmi") from Nimbus Therapeutics,...
USFDA nod to Takeda TAKHZYRO to prevent Hereditary Angioedema attacks in children 2 years of age and older Ruchika Sharma4 Feb 2023 1:15 PM ISTHereditary angioedema (HAE) is a rare genetic disorder that results in recurring attacks of edema - swelling - in various parts of the body, including...
